foscarnet has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hsu, SC; Hsu, YJ; Huang, SM; Lee, HS; Lin, CY; Lin, SH; Shih, CC; Tsai, CS | 1 |
1 review(s) available for foscarnet and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for foscarnet and sirolimus
| Article | Year |
|---|---|
Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling.
Topics: Adenine; Animals; Autophagy; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Foscarnet; Humans; Hyperphosphatemia; Male; Microtubule-Associated Proteins; Phosphates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats, Wistar; Renal Insufficiency, Chronic; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transfection | 2015 |